Abivax: M&A Premium Vanishes After Obefazimod Phase 3 Safety Signal
Source: SeekingAlpha
2026-06-02 10:58:00 ET
Abivax Overview
Investors were caught by surprise yesterday when ABIVAX Société Anonyme ( ABVX ) revealed Phase 3 maintenance data for its novel drug, obefazimod, in ulcerative colitis. Despite both doses meeting primary and all key secondary endpoints, the stock plummeted over 30% in after-hours trading Monday. Some may have been concerned about the apparent clustering of malignancy cases in high-dose (50 mg) obefazimod (more on this below)....
Read the full article on Seeking Alpha
For further details see:
Abivax: M&A Premium Vanishes After Obefazimod Phase 3 Safety Signal
Abivax SA
NASDAQ: ABVX
ABVX Trading
3.27% G/L:
$99.835 Last:
1,550,008 Volume:
$105.18 Open:
ABVX Latest News
June 03, 2026 08:53:00 pm
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 02, 2026 09:20:00 pm
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
ABVX Stock Data
$9,359,969,582
53,161,297
N/A
64
N/A
Biotechnology & Life Sciences
Healthcare
FR
Paris
